Company profile
TuHURA Biosciences, Inc. logo

TuHURA Biosciences, Inc.

Pipeline3 assets

  • IFx-2.0plasmid DNA (innate immune agonist) / Oncology
    Advanced or metastatic Merkel cell carcinoma (first-line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMetastatic Merkel cell carcinoma of unknown primary (MCCUP, first-line)Phase 1b/2aOngoingUnited States
  • TBS-2025VISTA / monoclonal antibody / Oncology
    NPM1-mutated relapsed/refractory AML (with menin inhibitor)Phase 1b/2PlannedUnited States
  • DOR bi-specific ADCDelta opioid receptor (DOR) on MDSCs/TAMs / antibody-drug conjugate (ADC) / Oncology
    Acute myeloid leukemia (AML)PreclinicalLead selection

Latest news12 items

All news